These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 34145944)

  • 61. Long-term denosumab treatment restores cortical bone loss and reduces fracture risk at the forearm and humerus: analyses from the FREEDOM Extension cross-over group.
    Bilezikian JP; Lin CJF; Brown JP; Wang AT; Yin X; Ebeling PR; Fahrleitner-Pammer A; Franek E; Gilchrist N; Miller PD; Simon JA; Valter I; Zerbini CAF; Libanati C; Chines A
    Osteoporos Int; 2019 Sep; 30(9):1855-1864. PubMed ID: 31201481
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Rebound vertebral and non-vertebral fractures during denosumab interruption in a postmenopausal woman.
    De Sousa SMC; Jesudason D
    Clin Endocrinol (Oxf); 2019 Jan; 90(1):250-252. PubMed ID: 30269340
    [No Abstract]   [Full Text] [Related]  

  • 63. Romosozumab Treatment in Postmenopausal Women with Osteoporosis.
    Cosman F; Crittenden DB; Adachi JD; Binkley N; Czerwinski E; Ferrari S; Hofbauer LC; Lau E; Lewiecki EM; Miyauchi A; Zerbini CA; Milmont CE; Chen L; Maddox J; Meisner PD; Libanati C; Grauer A
    N Engl J Med; 2016 Oct; 375(16):1532-1543. PubMed ID: 27641143
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Spontaneous Vertebral Fractures in Males with Osteoporosis After Denosumab Discontinuation: A Report of Two Cases.
    Anagnostis P; Paschou SA; Gonzalez-Rodriguez E; Potoupnis M; Tsiridis E; Lamy O; Goulis DG
    J Clin Rheumatol; 2021 Dec; 27(8S):S581-S584. PubMed ID: 30614889
    [No Abstract]   [Full Text] [Related]  

  • 65. Drug efficacies on bone mineral density and fracture rate for the treatment of postmenopausal osteoporosis: a network meta-analysis.
    Yang L; Kang N; Yang JC; Su QJ; Liu YZ; Guan L; Liu T; Meng XL; Wang Y; Hai Y
    Eur Rev Med Pharmacol Sci; 2019 Mar; 23(6):2640-2668. PubMed ID: 30964193
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effects of bone remodeling agents following teriparatide treatment.
    Burkard D; Beckett T; Kourtjian E; Messingschlager C; Sipahi R; Padley M; Stubbart J
    Osteoporos Int; 2018 Jun; 29(6):1351-1357. PubMed ID: 29541794
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Similar relationship between the time course of bone mineral density improvement and vertebral fracture risk reduction with denosumab treatment in postmenopausal osteoporosis and prostate cancer patients on androgen deprivation therapy.
    Pérez Ruixo JJ; Zheng J; Mandema JW
    J Clin Pharmacol; 2014 May; 54(5):503-12. PubMed ID: 24214315
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Management of postmenopausal osteoporosis and the prevention of fractures.
    Gambacciani M; Levancini M
    Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Comparison of proximal femur and vertebral body strength improvements in the FREEDOM trial using an alternative finite element methodology.
    Zysset P; Pahr D; Engelke K; Genant HK; McClung MR; Kendler DL; Recknor C; Kinzl M; Schwiedrzik J; Museyko O; Wang A; Libanati C
    Bone; 2015 Dec; 81():122-130. PubMed ID: 26141837
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Variability of Denosumab densitometric response in postmenopausal osteoporosis.
    Laroche M; Baradat C; Ruyssen-Witrand A; Degboe Y
    Rheumatol Int; 2018 Mar; 38(3):461-466. PubMed ID: 29362876
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Denosumab in postmenopausal women with low bone mineral density.
    McClung MR; Lewiecki EM; Cohen SB; Bolognese MA; Woodson GC; Moffett AH; Peacock M; Miller PD; Lederman SN; Chesnut CH; Lain D; Kivitz AJ; Holloway DL; Zhang C; Peterson MC; Bekker PJ;
    N Engl J Med; 2006 Feb; 354(8):821-31. PubMed ID: 16495394
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Study of the psycho-emotional disorders' severity in patients with osteoporotic vertebral fractures and factors affecting them].
    Marchenkova LA; Fesyun AD; Gerasimenko MY
    Vopr Kurortol Fizioter Lech Fiz Kult; 2021; 98(3):18-28. PubMed ID: 34223751
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis.
    Makras P; Papapoulos SE; Polyzos SA; Appelman-Dijkstra NM; Anastasilakis AD
    Bone; 2020 Sep; 138():115478. PubMed ID: 32534221
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Letter to the Editor: Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Nine Clinical Cases Report.
    Trovas G
    J Clin Endocrinol Metab; 2017 Mar; 102(3):1086. PubMed ID: 28359104
    [No Abstract]   [Full Text] [Related]  

  • 75. Treatment with denosumab reduces secondary fracture risk in women with postmenopausal osteoporosis.
    Palacios S; Kalouche-Khalil L; Rizzoli R; Zapalowski C; Resch H; Adachi JD; Gallagher JC; Feldman RG; Kendler DL; Wang A; Wagman RB; Adami S
    Climacteric; 2015; 18(6):805-12. PubMed ID: 26029985
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial.
    Miller PD; Wagman RB; Peacock M; Lewiecki EM; Bolognese MA; Weinstein RL; Ding B; San Martin J; McClung MR
    J Clin Endocrinol Metab; 2011 Feb; 96(2):394-402. PubMed ID: 21159841
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Treatment of high fracture risk patients in routine clinical practice.
    Lesnyak O; Gladkova E; Aleksandrov N; Belaya Z; Belova K; Bezlyudnaya N; Dobrovolskaya O; Dreval A; Ershova O; Grebennikova T; Kryukova I; Mazurenko S; Priymak D; Rozhinskaya L; Samigullina R; Solodovnikov A; Toroptsova N
    Arch Osteoporos; 2020 Nov; 15(1):184. PubMed ID: 33219455
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Denosumab. Limited efficacy in fracture prevention, too many adverse effects.
    Prescrire Int; 2011 Jun; 20(117):145-8. PubMed ID: 21678700
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Denosumab densitometric changes assessed by quantitative computed tomography at the spine and hip in postmenopausal women with osteoporosis.
    McClung MR; Zanchetta JR; Høiseth A; Kendler DL; Yuen CK; Brown JP; Stonkus S; Goemaere S; Recknor C; Woodson GC; Bolognese MA; Franek E; Brandi ML; Wang A; Libanati C
    J Clin Densitom; 2013; 16(2):250-6. PubMed ID: 22572531
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Wensel TM; Iranikhah MM; Wilborn TW
    Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.